Rubella antibodies and adverse events late after renal transplantation

J. P. Luby, A. J. Ware, P. Vergne-Marini, P. Stastny, A. R. Hull

Research output: Contribution to journalArticle

Abstract

Rubella antibody titers were determined pretransplant and then serially posttransplantation in 52 consecutive patients whose renal allografts survived at least three months. Group A patients (18) had antibody titers ≥1:128 in the posttransplant period. Group B (24) had intermediate antibody titers that never rose higher than 1:64. Group C (10) consistently had antibody titers <1:8. Group A did not differ from groups B and C with respect to age, race, sex, type of transplant, underlying renal disease, or maximum complement fixation antibody titer posttransplant to cytomegalovirus and herpes simplex virus, type 1. Group A did differ from groups B and C in its frequency of hepatitis, chronic liver disease, episodes of late rejection (≥21 21 days after transplant), transplant nephrectomy required for rejection, infections whose defense involves intact cell-mediated immunity, and the number of late rejection episodes per patient. Mechanisms underlying these associations are not known but apparently are not related to HLA phenotype.

Original languageEnglish (US)
Pages (from-to)33-35
Number of pages3
JournalArchives of Internal Medicine
Volume139
Issue number1
DOIs
StatePublished - 1979

Fingerprint

Kidney Transplantation
Antibodies
Transplants
Kidney
Human Herpesvirus 1
Nephrectomy
Cytomegalovirus
Cellular Immunity
Hepatitis
Allografts
Liver Diseases
Chronic Disease
Phenotype
rubella antibodies
Infection

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Rubella antibodies and adverse events late after renal transplantation. / Luby, J. P.; Ware, A. J.; Vergne-Marini, P.; Stastny, P.; Hull, A. R.

In: Archives of Internal Medicine, Vol. 139, No. 1, 1979, p. 33-35.

Research output: Contribution to journalArticle

Luby, J. P. ; Ware, A. J. ; Vergne-Marini, P. ; Stastny, P. ; Hull, A. R. / Rubella antibodies and adverse events late after renal transplantation. In: Archives of Internal Medicine. 1979 ; Vol. 139, No. 1. pp. 33-35.
@article{b5a89f2b6c064fdfb10580e7eb7a9e9e,
title = "Rubella antibodies and adverse events late after renal transplantation",
abstract = "Rubella antibody titers were determined pretransplant and then serially posttransplantation in 52 consecutive patients whose renal allografts survived at least three months. Group A patients (18) had antibody titers ≥1:128 in the posttransplant period. Group B (24) had intermediate antibody titers that never rose higher than 1:64. Group C (10) consistently had antibody titers <1:8. Group A did not differ from groups B and C with respect to age, race, sex, type of transplant, underlying renal disease, or maximum complement fixation antibody titer posttransplant to cytomegalovirus and herpes simplex virus, type 1. Group A did differ from groups B and C in its frequency of hepatitis, chronic liver disease, episodes of late rejection (≥21 21 days after transplant), transplant nephrectomy required for rejection, infections whose defense involves intact cell-mediated immunity, and the number of late rejection episodes per patient. Mechanisms underlying these associations are not known but apparently are not related to HLA phenotype.",
author = "Luby, {J. P.} and Ware, {A. J.} and P. Vergne-Marini and P. Stastny and Hull, {A. R.}",
year = "1979",
doi = "10.1001/archinte.139.1.33",
language = "English (US)",
volume = "139",
pages = "33--35",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Rubella antibodies and adverse events late after renal transplantation

AU - Luby, J. P.

AU - Ware, A. J.

AU - Vergne-Marini, P.

AU - Stastny, P.

AU - Hull, A. R.

PY - 1979

Y1 - 1979

N2 - Rubella antibody titers were determined pretransplant and then serially posttransplantation in 52 consecutive patients whose renal allografts survived at least three months. Group A patients (18) had antibody titers ≥1:128 in the posttransplant period. Group B (24) had intermediate antibody titers that never rose higher than 1:64. Group C (10) consistently had antibody titers <1:8. Group A did not differ from groups B and C with respect to age, race, sex, type of transplant, underlying renal disease, or maximum complement fixation antibody titer posttransplant to cytomegalovirus and herpes simplex virus, type 1. Group A did differ from groups B and C in its frequency of hepatitis, chronic liver disease, episodes of late rejection (≥21 21 days after transplant), transplant nephrectomy required for rejection, infections whose defense involves intact cell-mediated immunity, and the number of late rejection episodes per patient. Mechanisms underlying these associations are not known but apparently are not related to HLA phenotype.

AB - Rubella antibody titers were determined pretransplant and then serially posttransplantation in 52 consecutive patients whose renal allografts survived at least three months. Group A patients (18) had antibody titers ≥1:128 in the posttransplant period. Group B (24) had intermediate antibody titers that never rose higher than 1:64. Group C (10) consistently had antibody titers <1:8. Group A did not differ from groups B and C with respect to age, race, sex, type of transplant, underlying renal disease, or maximum complement fixation antibody titer posttransplant to cytomegalovirus and herpes simplex virus, type 1. Group A did differ from groups B and C in its frequency of hepatitis, chronic liver disease, episodes of late rejection (≥21 21 days after transplant), transplant nephrectomy required for rejection, infections whose defense involves intact cell-mediated immunity, and the number of late rejection episodes per patient. Mechanisms underlying these associations are not known but apparently are not related to HLA phenotype.

UR - http://www.scopus.com/inward/record.url?scp=0018579655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018579655&partnerID=8YFLogxK

U2 - 10.1001/archinte.139.1.33

DO - 10.1001/archinte.139.1.33

M3 - Article

C2 - 367306

VL - 139

SP - 33

EP - 35

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 1

ER -